内容摘要：, a 2022 reflection on her decades spent entertaining friends in

, a 2022 reflection on her decades spent entertaining friends in

found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head trial with semaglutide (Ozempic, Wegovy). It's important to point out that the study was funded by the company that makes Zepbound. But experts aren't surprised by the findings.Of course, if you’re interested in taking a weight-loss medication, it’s fair to wonder if Zepbound might be a better choice. Here’s what the study found, plus what a weight-loss doctor wants people to keep in mind when taking in this new information.

MD, is a medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CAFor the study, researchers had 751 people with obesity (but without type 2 diabetes) take either the maximum tolerated dose of tirzepatide or the maximum tolerated dose of semaglutide once a week for 72 weeks.At the end of the 72 weeks, people who took tirzepatide lost an average of 50 pounds or about 20.2 percent of their body weight. Participants who took semaglutide lost an average of 33 pounds or 13.7 percent of their body weight. People who took tirzepatide also had bigger reductions in waist size compared to those who took semaglutide.

“Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72,” the researchers wrote in the conclusion.MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, isn’t shocked by the findings.

“Zepbound operates on two receptors that suppress the appetite and slow motility in the gastrointestinal tract—the GLP-1 and GIP receptors,” he explains. “Semaglutide only affects the GLP-1 receptor.” So, since Zepbound acts on more than one receptor “it makes sense that it would have a stronger effect on appetite and ultimately work better,” Dr. Ali says.

which also makes fellow tirzepatide medication Mounjaro. (Ozempic is made byHowever, HHS and the Centers for Medicare and Medicaid Services (CMS) rescinded the guidance, as well as an

saying they "do not reflect the policy of this Administration.""CMS will continue to enforce EMTALA, which protects all individuals who present to a hospital emergency department seeking examination or treatment, including for identified emergency medical conditions that place the health of a pregnant woman or her unborn child in serious jeopardy," a press release from the agency read.

"CMS will work to rectify any perceived legal confusion and instability created by the former administration's actions," the press release continued.Abortion rights groups, such as the American Civil Liberties Union, criticized the administration and accused President Donald Trump of walking back on a campaign promise not to interfere with abortion access.